The Korean Journal of Food And Nutrition (한국식품영양학회지)

The Korean Society of Food and Nutrition (한국식품영양학회)
권호 표지
DOI QR코드

DOI QR Code

Effects of HX106N, a Water-Soluble Botanical Formulation on Scopolamine-Induced Memory Impairment in Mice

식물성 열수 추출물 HX106N이 스코폴라민으로 유도한 생쥐 기억력 저하에 미치는 효과에 관한 연구

  • 이두석 (서울대학교 자연과학대학 생명과학부) ;
  • 정재균 ((주)바이로메드) ;
  • 김선영 (서울대학교 자연과학대학 생명과학부)
  • Received : 2014.05.07
  • Accepted : 2014.08.13
  • Published : 2014.08.30
Download PDF
⟨ Previous Next ⟩

Abstract

HX106N은 용안육, 맥문동, 단삼 및 천마 등의 4가지 식물로 구성된 추출물로서, 선행 연구에서 amyloid ${\beta}$ peptide에 의한 생쥐의 기억력 저하 및 산화 손상을 억제하는 것으로 밝혀졌다. 이 연구에서는 HX106N이 비선택적 무스카린 수용체 길항제로 잘 알려진 스코폴라민(scopolamine)으로 유도한 콜린성 건망증(cholinergic amnesia)에 어떤 영향을 미치는지를 평가하였다. ICR 생쥐에게 스코폴라민(1 mg/kg body weight, i.p.)을 주입하기 1시간 전에 HX106N(100 mg/kg body weight, p.o.)을 투여하였다. 30분 후 수행한 Y-미로 시험(Y-maze test) 및 수동 회피 시험(passive avoidance test)에서 HX106N는 스코폴라민에 의해 감소되는 자발적 변경 행동(spontaneous alternation) 및 지체시간(step-through latency)을 유의미하게 억제하여 건망증을 개선시키는 것으로 나타났다. 또한 HX106N을 투약 1시간 후 생쥐의 해마와 대뇌피질 부위의 아세틸콜린에스테라제(acetylcholinesterase; AChE)의 활성을 측정한 결과 통계적으로 유의미한 정도의 활성 감소가 관찰되었다. 이러한 결과들을 종합할 때 HX106N은 AD에서 관찰되는 콜린성신경전달 장애로 인한 기억력 저하 억제에 사용될 수 있는 가능성을 가진 것으로 판단된다.

Keywords

References

  1. Babic T, Francis P, Palmer A, Snape M, Wilcock G. 1999. The cholinergic hypothesis of Alzheimer's disease: A review of progress. J Neurol Neurosurg Psychiatry 66:137-147 https://doi.org/10.1136/jnnp.66.2.137
  2. Benzi G, Moretti A, 1998. Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease? Eur J Pharmacol 346:1-13 https://doi.org/10.1016/S0014-2999(98)00093-4
  3. Biederman J, Mick E, Faraone S, Hammerness P, Surman C, Harpold T, Dougherty M, Aleardi M, Spencer T. 2006. A double-blind comparison of galantamine hydrogen bromide and placebo in adults with attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychopharmacol 26:163-166 https://doi.org/10.1097/01.jcp.0000204139.20417.8a
  4. Cubo E, Fernandez Jaen A, Moreno C, Anaya B, Gonzalez M, Kompoliti K. 2008. Donepezil use in children and adolescents with tics and attention-deficit/hyperactivity disorder: an 18-week, single-center, dose-escalating, prospective, openlabel study. Clin Ther 30:182-189 https://doi.org/10.1016/j.clinthera.2008.01.010
  5. Hirai S. 2000. Alzheimer disease: current therapy and future therapeutic strategies. Alzheimer Dis Assoc Disord 14 Suppl 1:S11-17
  6. Klinkenberg I, Blokland A. 2010. The validity of scopolamine as a pharmacological model for cognitive impairment: A review of animal behavioral studies. Neurosci Biobehav Rev 34:1307-1350 https://doi.org/10.1016/j.neubiorev.2010.04.001
  7. Kosasa T, Kuriya Y, Matsui K, Yamanishi Y. 1999. Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats. Eur J Pharmacol 380:101-107 https://doi.org/10.1016/S0014-2999(99)00545-2
  8. Lee DS, Choi J, Kim SH, Kim S. 2014. Ameliorating effects of HX106N, a water-soluble botanical formulation, on Abetainduced memory impairment and oxidative stress in mice. Biol Pharm Bull 37:954-960 https://doi.org/10.1248/bpb.b13-00906
  9. Maurice T, Lockhart BP, Privat A. 1996. Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res 706:181-193 https://doi.org/10.1016/0006-8993(95)01032-7
  10. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. 1998. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 50:136-145 https://doi.org/10.1212/WNL.50.1.136
  11. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M. 1999. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 318: 633-638
  12. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. 2000. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 54:2269-2276 https://doi.org/10.1212/WNL.54.12.2269
  13. Terry AV Jr, Buccafusco JJ. 2003. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 306:821-827 https://doi.org/10.1124/jpet.102.041616
  14. Tran MH, Yamada K, Nabeshima T. 2002. Amyloid beta-peptide induces cholinergic dysfunction and cognitive deficits: A minireview. Peptides 23:1271-1283 https://doi.org/10.1016/S0196-9781(02)00062-1

Cited by

  1. Effective suppression of nitric oxide production by HX106N through transcriptional control of heme oxygenase-1 vol.240, pp.9, 2015, https://doi.org/10.1177/1535370214567612